Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) shares were up 6.6% on Thursday . The stock traded as high as $5.07 and last traded at $5.07. Approximately 385,039 shares were traded during trading, a decline of 72% from the average daily volume of 1,382,450 shares. The stock had previously closed at $4.76.
Analyst Ratings Changes
Several equities analysts recently weighed in on VIR shares. HC Wainwright reaffirmed a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, February 28th. The Goldman Sachs Group cut their target price on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Barclays lifted their price objective on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $14.00 price objective on shares of Vir Biotechnology in a research note on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $32.86.
View Our Latest Stock Report on VIR
Vir Biotechnology Stock Performance
The company's fifty day moving average price is $5.50 and its 200-day moving average price is $7.52. The stock has a market cap of $671.84 million, a P/E ratio of -1.24 and a beta of 1.36.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.05). The firm had revenue of $3.03 million during the quarter, compared to the consensus estimate of $8.59 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. Vir Biotechnology's revenue was down 94.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.48) EPS. Analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, CEO Backer Marianne De sold 79,712 shares of the firm's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total value of $474,286.40. Following the transaction, the chief executive officer now owns 769,505 shares of the company's stock, valued at $4,578,554.75. This trade represents a 9.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 16.00% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its stake in Vir Biotechnology by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company's stock worth $16,127,000 after buying an additional 7,827 shares during the period. Dimensional Fund Advisors LP increased its position in Vir Biotechnology by 58.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company's stock valued at $14,059,000 after purchasing an additional 703,360 shares during the period. Millennium Management LLC increased its position in Vir Biotechnology by 55.3% during the 4th quarter. Millennium Management LLC now owns 1,715,083 shares of the company's stock valued at $12,589,000 after purchasing an additional 610,367 shares during the period. Charles Schwab Investment Management Inc. increased its position in Vir Biotechnology by 9.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,374,874 shares of the company's stock valued at $8,909,000 after purchasing an additional 122,219 shares during the period. Finally, Renaissance Technologies LLC increased its position in Vir Biotechnology by 4.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,237,600 shares of the company's stock valued at $9,084,000 after purchasing an additional 55,300 shares during the period. Hedge funds and other institutional investors own 65.32% of the company's stock.
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Recommended Stories
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
